Cargando…
Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezloto...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792623/ https://www.ncbi.nlm.nih.gov/pubmed/33374989 http://dx.doi.org/10.3390/jcm10010002 |
_version_ | 1783633844336852992 |
---|---|
author | Escudero-Sánchez, Rosa Ruiz-Ruigómez, María Fernández-Fradejas, Jorge García Fernández, Sergio Olmedo Samperio, María Cano Yuste, Angela Valencia Alijo, Angela Díaz-Pollán, Beatriz Rodríguez Hernández, María Jesús Merino De Lucas, Esperanza Martín Segarra, Oriol Sáez Bejar, Carmen Armiñanzas Castillo, Carlos Gutiérrez-Gutiérrez, Belén Rodríguez-Pardo, Dolors Ramos-Martínez, Antonio Torre-Cisneros, Julián López-Medrano, Francisco Cobo Reinoso, Javier |
author_facet | Escudero-Sánchez, Rosa Ruiz-Ruigómez, María Fernández-Fradejas, Jorge García Fernández, Sergio Olmedo Samperio, María Cano Yuste, Angela Valencia Alijo, Angela Díaz-Pollán, Beatriz Rodríguez Hernández, María Jesús Merino De Lucas, Esperanza Martín Segarra, Oriol Sáez Bejar, Carmen Armiñanzas Castillo, Carlos Gutiérrez-Gutiérrez, Belén Rodríguez-Pardo, Dolors Ramos-Martínez, Antonio Torre-Cisneros, Julián López-Medrano, Francisco Cobo Reinoso, Javier |
author_sort | Escudero-Sánchez, Rosa |
collection | PubMed |
description | Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the real world. A retrospective, multicentre cohort study of patients treated with bezlotoxumab in Spain was conducted. We compared the characteristics of cohort patients with those of patients treated with bezlotoxumab in the pivotal MODIFY trials. We assessed recurrence rates 12 weeks after completion of treatment against C. difficile, and we analysed the factors associated with bezlotoxumab failure. Ninety-one patients were included in the study. The cohort presented with more risk factors for rCDI than the patients included in the MODIFY trials. Thirteen (14.2%) developed rCDI at 12 weeks of follow-up, and rCDI rates were numerically higher in patients with two or more previous episodes (25%) than in those who had fewer than two previous episodes of C. difficile infection (CDI) (10.4%); p = 0.09. There were no adverse effects attributable to bezlotoxumab. Despite being used in a more compromised population than that represented in clinical trials, we confirm the effectiveness of bezlotoxumab for the prevention of rCDI. |
format | Online Article Text |
id | pubmed-7792623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77926232021-01-09 Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection Escudero-Sánchez, Rosa Ruiz-Ruigómez, María Fernández-Fradejas, Jorge García Fernández, Sergio Olmedo Samperio, María Cano Yuste, Angela Valencia Alijo, Angela Díaz-Pollán, Beatriz Rodríguez Hernández, María Jesús Merino De Lucas, Esperanza Martín Segarra, Oriol Sáez Bejar, Carmen Armiñanzas Castillo, Carlos Gutiérrez-Gutiérrez, Belén Rodríguez-Pardo, Dolors Ramos-Martínez, Antonio Torre-Cisneros, Julián López-Medrano, Francisco Cobo Reinoso, Javier J Clin Med Article Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the real world. A retrospective, multicentre cohort study of patients treated with bezlotoxumab in Spain was conducted. We compared the characteristics of cohort patients with those of patients treated with bezlotoxumab in the pivotal MODIFY trials. We assessed recurrence rates 12 weeks after completion of treatment against C. difficile, and we analysed the factors associated with bezlotoxumab failure. Ninety-one patients were included in the study. The cohort presented with more risk factors for rCDI than the patients included in the MODIFY trials. Thirteen (14.2%) developed rCDI at 12 weeks of follow-up, and rCDI rates were numerically higher in patients with two or more previous episodes (25%) than in those who had fewer than two previous episodes of C. difficile infection (CDI) (10.4%); p = 0.09. There were no adverse effects attributable to bezlotoxumab. Despite being used in a more compromised population than that represented in clinical trials, we confirm the effectiveness of bezlotoxumab for the prevention of rCDI. MDPI 2020-12-22 /pmc/articles/PMC7792623/ /pubmed/33374989 http://dx.doi.org/10.3390/jcm10010002 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Escudero-Sánchez, Rosa Ruiz-Ruigómez, María Fernández-Fradejas, Jorge García Fernández, Sergio Olmedo Samperio, María Cano Yuste, Angela Valencia Alijo, Angela Díaz-Pollán, Beatriz Rodríguez Hernández, María Jesús Merino De Lucas, Esperanza Martín Segarra, Oriol Sáez Bejar, Carmen Armiñanzas Castillo, Carlos Gutiérrez-Gutiérrez, Belén Rodríguez-Pardo, Dolors Ramos-Martínez, Antonio Torre-Cisneros, Julián López-Medrano, Francisco Cobo Reinoso, Javier Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection |
title | Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection |
title_full | Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection |
title_fullStr | Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection |
title_full_unstemmed | Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection |
title_short | Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection |
title_sort | real-world experience with bezlotoxumab for prevention of recurrence of clostridioides difficile infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792623/ https://www.ncbi.nlm.nih.gov/pubmed/33374989 http://dx.doi.org/10.3390/jcm10010002 |
work_keys_str_mv | AT escuderosanchezrosa realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT ruizruigomezmaria realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT fernandezfradejasjorge realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT garciafernandezsergio realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT olmedosamperiomaria realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT canoyusteangela realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT valenciaalijoangela realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT diazpollanbeatriz realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT rodriguezhernandezmariajesus realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT merinodelucasesperanza realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT martinsegarraoriol realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT saezbejarcarmen realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT arminanzascastillocarlos realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT gutierrezgutierrezbelen realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT rodriguezpardodolors realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT ramosmartinezantonio realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT torrecisnerosjulian realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT lopezmedranofrancisco realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection AT coboreinosojavier realworldexperiencewithbezlotoxumabforpreventionofrecurrenceofclostridioidesdifficileinfection |